About us

Board of directors

Peter Ehrenheim

Chairman of the Board
Elected to the board:
September 9, 2019

Peter has an operative background from Pharmacia Biotech, Amersham and GE Healthcare. He was general manager for Separations Division 1999-2006, and from 2006-2011, general manager for GE’s Life Sciences business which was acquired by Danaher in 2020. From 2011, he has worked as an entrepreneur with different companies and board roles. He  is presently chairman in Färjsundet Industri AB and Sophion A/S, and a board member at Biotage AB and Grönsöö Säteri AB. 

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Dr. Kirsti Gjellan

Board director
Elected to the board:
May 18, 2018

Kirsti has more than 30 years of experience from the life science and pharmaceutical industries. She has previously held leading and executive positions at AstraZeneca, Pfizer and Swedish Orphan Biovitrim (Sobi), and was managing director for Pfizer Health AB during 2011-2014. She has held previous board assignments at Pfizer Health AB, PiiA, SwedenBio, OxThera AB and Envirotainer Holding AB. Kirsti is the founder and chairman of Kirsti Gjellan AB and holds current board assignments at the Royal Institute of Technology (KTH) and Xbrane Biopharma AB. 

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Johan Sedihn

Board director
Elected to the board:
May 15, 2020

Johan Sedihn has more than 30 years of experience in the medical technology industry and Elekta Group. He has been involved in building operations during Elekta's growth in roles such as Executive VP Oncology and Chief Operating Officer, during which time he was part of Elekta's Group Management for 13 years. Johan has experience from several board assignments and he is presently chairman of the board at SyntheticMR AB (publ), Dirac Research AB (publ) and Sedvisor Limited.  

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Peter Nählstedt

Board director
Elected to the board:
May 15, 2020

Peter Nählstedt has more than 20 years of operational experience from leading positions in life science and industry. His experience includes CEO of Probi AB (publ), Director Europe Trelleborg Marine Systems and General Manager North America BioProcess at GE Healthcare. He has also worked as consultant and advisor and held roles in marketing, sales and strategy at Sigma-Aldrich and GE Healthcare. Today he works as CEO of SenzaGen AB (publ) and is chairman of the board at Supersynbiotics AB and holds board positions at Bio-Works and Optiome AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Name Title Shares Options or warrants
Peter Ehrenheim Chairman of the Board 260 677 and 1 284 323 via Färjsundet AB
Dr. Kirsti Gjellan Board director 90 456
Johan Sedihn Board director 133 526
Peter Nählstedt Board director 21 700
Shareholding information last updated 2024-05-18